Literature DB >> 12679704

Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use.

Anita Palepu1, Mark Tyndall, Benita Yip, Michael V O'Shaughnessy, Robert S Hogg, Julio S G Montaner.   

Abstract

Injection drug users who continue to use drugs may not respond to highly active antiretroviral therapy (HAART) as well as other HIV-infected individuals, even after adjusting for a reliable measure of adherence. We therefore compared the virologic response among participants in a population-based HIV/AIDS Drug Treatment Program in British Columbia, Canada, by injection drug use activity. Participants who were HIV infected and naive to antiretroviral therapy and who were prescribed antiretroviral treatment between August 1996 and December 2000 were eligible for this study. They were classified as current, former, or non-injection drug users. The main outcome was having two consecutive HIV-1 RNA levels less than 500 copies/mL. We used logistic regression to adjust for baseline HIV-1 RNA, type of antiretroviral regimen (2 nucleosides + nonnucleoside reverse transcriptase inhibitor versus 2 nucleosides + protease inhibitor), duration of therapy (months), adherence (derived from refill compliance data), and age. A total of 578 participants were first prescribed HAART during the study period. Among them, 78 (13%) were current injection drug users, 96 (17%) were former injection drug users, and 404 (70%) never injected drugs. In the multivariable logistic regression, relative to non-drug users, current injection drug users were significantly less likely to suppress their HIV-1 RNA (adjusted OR [AOR] = 0.30, 95% CI: 0.13-0.67), and former injection drug users were not significantly different from non-drug users (AOR = 0.56, 95% CI: 0.24-1.34). There was a significant interaction between drug use and adherence. In the analyses stratified by drug use, the adherence of former and non-drug users was positively associated with HIV-1 RNA suppression (AOR = 1.33, 95% CI: 1.14-1.55), whereas for current drug users, it was not (AOR = 1.07, 95% CI: 0.87-1.33). Current injection drug users were less likely to achieve HIV-1 RNA suppression compared with non-drug users. Adherence as measured by pharmacy refill compliance was not a reliable measure in this subpopulation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12679704     DOI: 10.1097/00126334-200304150-00009

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  56 in total

1.  Selection in context: patterns of natural selection in the glycoprotein 120 region of human immunodeficiency virus 1 within infected individuals.

Authors:  Alan R Templeton; Rebecca A Reichert; Anton E Weisstein; Xiao-Fang Yu; Richard B Markham
Journal:  Genetics       Date:  2004-08       Impact factor: 4.562

2.  Psychosocial factors in adherence to antiretroviral therapy among HIV-positive people who use drugs.

Authors:  William K Lee; M J S Milloy; John Walsh; Paul Nguyen; Evan Wood; Thomas Kerr
Journal:  Health Psychol       Date:  2015-12-21       Impact factor: 4.267

Review 3.  Measuring adherence to highly active antiretroviral therapy: implications for research and practice.

Authors:  Thomas Kerr; John Walsh; Elisa Lloyd-Smith; Evan Wood
Journal:  Curr HIV/AIDS Rep       Date:  2005-11       Impact factor: 5.071

4.  Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence.

Authors:  David J Moore; Kaitlin Blackstone; Steven Paul Woods; Ronald J Ellis; J Hampton Atkinson; Robert K Heaton; Igor Grant
Journal:  AIDS Care       Date:  2012-04-24

5.  The impact of illicit drug use and substance abuse treatment on adherence to HAART.

Authors:  P L Hicks; K P Mulvey; G Chander; J A Fleishman; J S Josephs; P T Korthuis; J Hellinger; P Gaist; K A Gebo
Journal:  AIDS Care       Date:  2007-10

6.  HIV-infected individuals who use alcohol and other drugs, and virologic suppression.

Authors:  Seonaid Nolan; Alexander Y Walley; Timothy C Heeren; Gregory J Patts; Alicia S Ventura; Meg M Sullivan; Jeffrey H Samet; Richard Saitz
Journal:  AIDS Care       Date:  2017-05-17

7.  Update on mental health issues in patients with HIV infection.

Authors:  Natalia Vlassova; Andrew F Angelino; Glenn J Treisman
Journal:  Curr Infect Dis Rep       Date:  2009-03       Impact factor: 3.725

8.  Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.

Authors:  Evan Wood; Julio S G Montaner; Benita Yip; Mark W Tyndall; Martin T Schechter; Michael V O'Shaughnessy; Robert S Hogg
Journal:  CMAJ       Date:  2003-09-30       Impact factor: 8.262

9.  The Impact of Substance Use on Adherence to Antiretroviral Therapy Among HIV-Infected Women in the United States.

Authors:  Yuehan Zhang; Tracey E Wilson; Adebola Adedimeji; Daniel Merenstein; Joel Milam; Jennifer Cohen; Mardge Cohen; Elizabeth T Golub
Journal:  AIDS Behav       Date:  2018-03

10.  HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use.

Authors:  Geetanjali Chander; Seth Himelhoch; John A Fleishman; James Hellinger; Paul Gaist; Richard D Moore; Kelly A Gebo
Journal:  AIDS Care       Date:  2009-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.